Cytosorbents Corp (NASDAQ: CTSO)

Cytosorbents Corp, known by its ticker symbol CTSO, is a pioneer in the treatment of life-threatening conditions in intensive care and cardiac surgery through blood purification, leveraging its unique polymer adsorption technology. The company's flagship product, CytoSorb, is a CE-marked extracorporeal cytokine adsorber that aims to reduce the cytokine storm or cytokine release syndrome, a common occurrence in critical illnesses that can lead to massive inflammation, organ failure, and even death.

Cytosorbents Corp's operations span across the globe, with a focus on developing and marketing innovative blood purification technologies. The company's products are designed to address a variety of medical conditions, including sepsis, trauma, burn injury, acute respiratory distress syndrome, pancreatitis, and liver failure, among others.

Cytosorbents Corp generates revenue primarily through the sale of its products, with CytoSorb being the primary revenue generator. CytoSorb is a biocompatible, highly porous polymer bead that actively removes toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The technology is protected by 19 issued U.S. patents and multiple international patents, with applications pending in the U.S. and internationally.

In addition to CytoSorb, the company has a number of product candidates under development based on its unique blood purification technology. These include CytoSorb XL, HemoDefend, ContrastSorb, DrugSorb, and DrugSorb-ATR, among others. CytoSorb has been used in various clinical trials and has received CE Mark approval in the European Union for use in clinical situations where cytokines are elevated.

Cytosorbents Corp's position within the industry is strengthened by its unique technology and the potential it has shown in clinical trials. The company's products are marketed and distributed directly in several countries, including Germany, Austria, Switzerland, Belgium, Luxembourg, Poland, Norway, Denmark, Sweden, the United Kingdom, and the Netherlands. The company is also exploring partnerships with major medical device companies to expand its reach.

The company's customers include Fresenius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group, among others. The total addressable market for CytoSorb in the U.S. and EU is estimated to be between $6 billion to $8 billion for the treatment of sepsis, between $500 million to $1 billion for the treatment of cardiac surgery, between $500 million to $1.25 billion for the treatment of ARDS and ALI, between $150 million to $350 million for the treatment of burn and smoke inhalation injury, between $1.5 billion to $2.0 billion for the treatment of trauma, more than $15 billion for the treatment of acute-on-chronic liver disease, acute hepatitis, and acute liver failure, between $400 million to $600 million for the treatment of severe acute pancreatitis, in excess of $4 billion for the treatment of cancer cachexia and cancer, and in excess of $6,000 for the treatment of brain-dead organ donors.

Cytosorbents Corp's market capitalization stands at approximately $1.3 billion, and the company has raised approximately $229 million from investors as of December 31, 2023.